Loading…
International Laboratories Corp, a drug manufacturer in Thailand, violated Current Good Manufacturing Practice (CGMP) regulations for finished pharmaceuticals during an FDA inspection conducted September 16-20, 2024. The company failed to maintain complete and reliable laboratory records for over-the-counter drug products and components, with investigators documenting multiple instances of fabricated laboratory records that were never actually performed—admissions confirmed by both the Laboratory Manager and a senior Quality Assurance Manager. This falsification of analytical testing data for raw materials and finished products rendered the firm's drug products adulterated under the Federal Food, Drug, and Cosmetic Act.